TME PHARM.CONF.IPO EO 1- Cash Flow-to-Debt Ratio
TME PHARM.CONF.IPO EO 1- cash flow-to-debt ratio. TME PHARM.CONF.IPO EO 1- (0N6A) has a Cash Flow-to-Debt Ratio of -0.92x as of December 2025, meaning its operating cash flow of €-3.42 Million could theoretically repay -1% of its total liabilities (€3.72 Million) in one year. See financial flexibility index of TME PHARM.CONF.IPO EO 1- to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of TME PHARM.CONF.IPO EO 1- (2021–2025)
Cash flow-to-debt ratio of TME PHARM.CONF.IPO EO 1- from 2021 to 2025. Historical debt coverage capacity for TME PHARM.CONF.IPO EO 1- across 5 annual periods. Also explore net asset growth rate of TME PHARM.CONF.IPO EO 1- to track the company's year-over-year net asset growth rate.
TME PHARM.CONF.IPO EO 1- Cash Flow-to-Debt Ratio by Year (2021–2025)
TME PHARM.CONF.IPO EO 1- cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for TME PHARM.CONF.IPO EO 1-. For the full cash flow conversion analysis, see cash flow conversion of TME PHARM.CONF.IPO EO 1-.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.92x | €-3.42 Million | €3.72 Million | ▲ +64.4% |
| 2024 | -2.59x | €-4.63 Million | €1.79 Million | ▼ -27.8% |
| 2023 | -2.02x | €-5.63 Million | €2.79 Million | ▼ -8.5% |
| 2022 | -1.86x | €-12.14 Million | €6.51 Million | ▲ +20.7% |
| 2021 | -2.35x | €-12.38 Million | €5.27 Million | — |